Indeed, targeting a single AKT isoform to counteract the function of the drivers relevant to a specific type of cancer would alleviate the toxicity observed when using pan-AKT inhibitors and be beneficial for patient outcome [28]. This evidence concerns the gene AKT1 and cancer.